GLYCOPHOS
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- GLYCOPHOS
- Generic name
- SODIUM GLYCEROPHOSPHATE
- Manufacturer
- Fresenius Kabi USA, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- e887e473-f1a7-40f1-bd6e-c99e7db7420d
- SPL ID
- 05761514-5960-44b8-8e1d-7f0a1ceeee2a
- Version
- 1
- Effective date
- 2026-10-08
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:07
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 220381 | derived:openfda.application_number |
| application number | NDA220381 | openfda.application_number | |
| brand name | GLYCOPHOS | openfda.brand_name | |
| generic name | SODIUM GLYCEROPHOSPHATE | openfda.generic_name | |
| manufacturer name | Fresenius Kabi USA, LLC | openfda.manufacturer_name | |
| ndc | package | 65219-348-10 | openfda.package_ndc |
| ndc | package | 65219-348-01 | openfda.package_ndc |
| ndc | package | 65219-346-01 | openfda.package_ndc |
| ndc | package | 65219-346-20 | openfda.package_ndc |
| ndc | product | 65219-346 | openfda.product_ndc |
| ndc | product | 65219-348 | openfda.product_ndc |
| ndc11 | package | 65219034801 | derived:openfda.package_ndc |
| ndc11 | package | 65219034601 | derived:openfda.package_ndc |
| ndc11 | package | 65219034620 | derived:openfda.package_ndc |
| ndc11 | package | 65219034810 | derived:openfda.package_ndc |
| rxcui | 1423812 | openfda.rxcui | |
| rxcui | 1423807 | openfda.rxcui | |
| rxcui | 2754772 | openfda.rxcui | |
| rxcui | 2754775 | openfda.rxcui | |
| spl id | 05761514-5960-44b8-8e1d-7f0a1ceeee2a | id | |
| spl set id | e887e473-f1a7-40f1-bd6e-c99e7db7420d | set_id | |
| unii | YP1H63LJ2K | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Pulmonary Embolism due to Pulmonary Vascular Precipitates : If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. ( 5.1 ) Hyperphosphatemia and Hypocalcemia : Monitor serum phosphorus and calcium concentrations during and following infusion. ( 5.2 ) Risk of Sodium Retention : Closely monitor patients with congestive heart failure, renal impairment, cirrhosis, and other conditions with risk for edema and/or sodium retention. Consider all sources of sodium, including concomitant use of sodium-retaining drugs, and adjust dose as needed. ( 5.3 ) Hypersensitivity Reactions: Monitor for signs or symptoms and discontinue infusion if reactions occur. ( 5.4 ) Aluminum Toxicity : Increased risk in patients with renal impairment, including preterm infants. ( 5.5 , 8.4 ) Hypomagnesemia : Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment. ( 5.6 ) Vein Damage and Thrombosis : Infuse concentrated or hyperosmolar solutions through a central catheter. ( 5.7 ) 5.1 Pulmonary Embolism Due to Pulmonary Vascular Precipitates Pulmonary vascular emboli and pulmonary distress related to precipitates in the pulmonary vasculature have been described in patients receiving admixed products containing calcium and phosphate or PN. The cause of precipitate formation has not been determined in all cases; however, in some fatal cases, pulmonary emboli occurred as a result of calcium phosphate precipitates. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation have also been reported. If signs of pulmonary distress occur, stop the PN infusion and initiate a medical evaluation. Visually inspect the prepared solution [see Dosage and Administration ( 2.2 , 2.3 )] , the infusion set, and catheter prior to administration as well as periodically during the administration. 5.2 Hyperphosphatemia and Hypocalcemia Hyperphosphatemia can occur with intravenous administration of phosphate-containing solutions, especially in patients with renal impairment. Hyperphosphatemia can cause the formation of insoluble calcium phosphorus products with consequent hypocalcemia, neurological irritability with tetany, nephrocalcinosis with acute kidney injury and, more rarely, cardiac irritability with arrhythmias. Obtain serum phosphorus and calcium concentrations prior to administration of Glycophos and normalize calcium before administering Glycophos [see Dosage and Administration ( 2.1 )] . Glycophos is contraindicated in patients with hyperphosphatemia and/or hypocalcemia [see Contraindications ( 4 )] . Glycophos containing PN admixtures should be infused slowly to avoid phosphorus intoxication and hypocalcemia [see Dosage and Administration ( 2.3 )]. Monitor serum phosphorus and calcium concentrations during treatment with Glycophos. 5.3 Risk of Sodium Retention Closely monitor patients with congestive heart failure, renal impairment, cirrhosis, and in other clinical states in which there exists edema and/or sodium retention during Glycophos use [see Use in Specific Populations ( 8.6 )] . The sodium content of Glycophos is 2 mEq/mL (46 mg/mL) and should be factored into the total sodium dose calculation for the prepared PN admixture. Concomitant use of Glycophos with sodium-retaining drugs (e.g., corticosteroids, corticotropin, non-steroidal anti-inflammatory agents) may lead to edema due to fluid retention. Patients should be monitored for swelling and weight gain. If edema occurs, consider dose adjustment or discontinuation of the sodium-retaining drug [see Drug Interactions ( 7.1 )]. 5.4 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported with Glycophos [see Adverse Reactions ( 6 )] . Glycophos is contraindicated in patients with a history of a hypersensitivity reaction to sodium glycerophosphate or any of the active or inactive ingredients [see Contraindications ( 4 )] . Stop administration of the PN admixture containing Glycophos immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated. 5.5 Aluminum Toxicity Glycophos contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Preterm neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including preterm neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Glycophos is not approved for use in pediatric patients less than 12 years of age, including preterm infants. Exposure to aluminum from Glycophos when administered at the maximum recommended dosage is not more than 0.5 mcg/kg/day [see Dosage and Administration ( 2.3 ), Description ( 11 )]. When prescribing Glycophos for use in PN solutions containing other small volume parenteral products, limit the total daily patient exposure to aluminum in the PN admixture to no more than 5 mcg/kg/day [see Use in Specific Populations ( 8.4 )] . 5.6 Hypomagnesemia Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia or diabetic ketoacidosis. Monitor serum magnesium concentrations during Glycophos treatment. 5.7 Vein Damage and Thrombosis Glycophos must be diluted and administered via intravenous infusion as an PN admixture. Do not infuse directly intravenously without dilution. The infusion of hyperosmolar solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral administration is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. If thrombophlebitis develops, remove the catheter as soon as possible and initiate appropriate medical treatment.PN admixtures containing Glycophos with an osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Dosage and Administration ( 2.1 )] . 5.8 Laboratory Monitoring Monitor serum phosphorus, sodium, calcium, and magnesium concentrations during treatment [see Dosage and Administration ( 2.1 , 2.2 , 2.3 )] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Pulmonary Embolism Due to Pulmonary Vascular Precipitates [see Warnings and Precautions ( 5.1 )]. Hyperphosphatemia and Hypocalcemia [see Warnings and Precautions ( 5.2 )]. Risk of Sodium Retention [see Warnings and Precautions ( 5.3 )]. Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )]. Aluminum Toxicity [see Warnings and Precautions ( 5.5 )]. Hypomagnesemia [see Warnings and Precautions ( 5.6 )]. Vein Damage and Thrombosis [see Warnings and Precautions ( 5.7 )]. The following adverse reactions associated with use of intravenous Glycophos ( Table 1 ) were identified in clinical studies or postmarketing reports. Given that some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. TABLE 1: Adverse Reactions Reported in Clinical Studies or Postmarketing Reports with Intravenous Glycophos System Organ Class Adverse Reactions Metabolism and Nutrition Disorders Hyperphosphatemia Hypocalcemia Hypernatremia Cardiac Disorders Hypotension, Arrhythmia, Heart block Cardiac arrest, Bradycardia, Chest pain, ECG changes Vascular Disorders Phlebitis Respiratory, Thoracic, and Mediastinal Disorders Dyspnea Renal and Urinary Disorders Acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury) Decreased urine output Chronic kidney disease Gastrointestinal Disorders Diarrhea, stomach pain Musculoskeletal and Connective Tissue Disorders Weakness Nervous System Disorders Confusion, lethargy, paralysis, paresthesia Skin and Subcutaneous Tissue Disorders Pruritus Rash Immune System Disorders Anaphylaxis Common adverse reactions include hyperphosphatemia, hypocalcemia, hypernatremia, and hypomagnesemia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table ID="t1" width="100%"> <caption>TABLE 1: Adverse Reactions Reported in Clinical Studies or Postmarketing Reports with Intravenous Glycophos </caption> <col width="52.500%" align="left"/> <col width="47.500%" align="left"/> <tbody> <tr> <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">System Organ Class </td> <td align="left" valign="top" styleCode="Toprule Botrule Rrule">Adverse Reactions </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Metabolism and Nutrition Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Hyperphosphatemia Hypocalcemia Hypernatremia </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Cardiac Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Hypotension, Arrhythmia, Heart block Cardiac arrest, Bradycardia, Chest pain, ECG changes </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Vascular Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Phlebitis </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Dyspnea </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Renal and Urinary Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury) Decreased urine output Chronic kidney disease </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Gastrointestinal Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Diarrhea, stomach pain </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Weakness </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Nervous System Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Confusion, lethargy, paralysis, paresthesia </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Skin and Subcutaneous Tissue Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Pruritus Rash </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="italics">Immune System Disorders</content> </td> <td align="left" valign="top" styleCode="Botrule Rrule">Anaphylaxis </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.